Medivir
Stockholm
About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. Medivir is a protease inhibitor design and the nucleotide/nucleoside science and we are dedicated to developing innovative pharmaceuticals that meet a great unmet medical need. Our commercial organization provides a portfolio of specialty care, pharmaceuticals on the Nordic market.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $45.5M
- Funding stage: IPO
- Last round: Post-IPO Debt (Oct 2024)
- Ticker: sto:MVIR
- Website: medivir.com
- Phone: +46 (0)85-468-3100
Industries & Categories
Biotechnology, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/medivir-154246 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.